First Report Customer Care 
All time: 4.6

Latest / Last 30 Days: 5.0

528 Reviews

Credit Rating - CALCICO THERAPEUTICS LIMITED

ANALYSIS
Credit Risk Update: ACCOUNTS DUE FLAG: CALCICO THERAPEUTICS LIMITED, Advent Life Sciences Ltd 158-160 North Gower Street, London, NW1 2ND. The legal status is a Private Limited Company and the current status at the registry of companies is Dissolved. The last filed accounts are dated 30 December 2018. The company was incorporated on 14 February 2012.

The accounts next due date is 30 September 2020. There are no mortgages.

The above was based on public record information as at 19 December 2024 and may not reflect the current status. Please access the current report to ascertain the current status and credit rating.
SUMMARY
Registered Number: 07948431
Date Incorporated: 14 February 2012
Date Latest Accounts: 30 December 2018
BUSINESS INFORMATION
Legal Form: Private Limited Company
Previous Names: None
Registered Number: 07948431
Annual Return: 14 February 2016
Registered Office: Advent Life Sciences Ltd 158-160 North Gower Street, London, NW1 2ND
SIC Code and Operations: 72110
SECURED CREDITORS
Number of Mortgages 0
Satisfied Mortgages 0
Part Satisfied Mortgages 0
Unsatisfied Mortgages 0
CREDIT RISK RATING
This is the credit risk assessment used by one of the top UK credit reference agencies.
Risk Score (1-100):

CALCICO THERAPEUTICS LIMITED

Click Here

to view this information

Risk Assessment:
Credit Rating:



First Report Score: (0-10):

Financial Status Guide:
10  trafficlight Very Strong
9   Strong
8 Very Good
7 Good
6 Above Average
5 Average
4 Below Average
3 Poor
2 Weak
1 Very Weak
0 Critical
Report Created On 29 December 2024 Copyright © 2024 First Report Ltd


Recent Searches

Reg No. Reg Name Status
04236304 CALCICOM LIMITED Liquidation
SC516361 CALCIFER LIMITED Active - Proposal to Strike off
12616710 CALCIFER LTD Active
10467754 CALCIFY LTD Active - Proposal to Strike off
12907389 CALCIHYDRITE LTD Active - Proposal to Strike off

In using this service you agree to the Terms and Conditions

© 2024 First Report Ltd